Arbutus Biopharma (ABUS) Stock Statistics & Valuation Metrics

Arbutus Biopharma has a market cap or net worth of $837.56M. The enterprise value is $814.48M.

Arbutus Biopharma has 197,537,700 shares outstanding. The number of shares has decreased by -2.65% in one year.

Arbutus Biopharma’s return on equity (ROE) is -0.44 and return on invested capital (ROIC) is -30.34%.

The current PE Ratio of Arbutus Biopharma is 1.3. Arbutus Biopharma’s PEG ratio is 0.50.

In the last 12 months, Arbutus Biopharma had revenue of 14.08M and earned -33.50M in profits. Earnings per share was -0.17.

In the last 12 months, operating cash flow was -34.36M and capital expenditures 4.00, giving a free cash flow of -34.36M billion.

Arbutus Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Arbutus Biopharma upcoming earnings date is Jul 30, 2026, After Close (Confirmed).

Arbutus Biopharma as a current ratio of 15.73, with Debt / Equity ratio of 0.24%

In the past 12 months, Arbutus Biopharma has paid 0.00 in taxes.

Arbutus Biopharma EV to EBITDA ratio is -34.01, with an EV/FCF ratio of -22.90.

Arbutus Biopharma has $95.23M in cash and marketable securities with $631.00K in debt, giving a net cash position of $94.59M billion.

Gross margin is 99.98%, with operating margin of -192.08%, and net profit margin of -237.88%.

The average price target for Arbutus Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―